All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
MARIPOSA, 2021 1.43 [0.42; 4.87]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.86 [0.67 ; 1.11 ] CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, MARIPOSA, 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021, Veiga, 2021 14 13% 2,457 moderate low death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EMPACTA, 2020 1.13 [0.54; 2.40]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVERY, 2021 0.85 [0.76; 0.95]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.85 [0.77 ; 0.92 ] BACC Bay Tocilizumab Trial, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Declercq J (COV-AID), 2021, EMPACTA, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 20 0% 8,295 moderate low deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.93 [0.71 ; 1.21 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021 4 6% 1,486 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
EMPACTA, 2020 0.55 [0.33; 0.92]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
0.76 [0.56 ; 1.05 ] BACC Bay Tocilizumab Trial, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021, Soin AS (COVINTOC), 2021 5 16% 674 moderate not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
EMPACTA, 2020 1.15 [0.90; 1.47]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
1.26 [1.04 ; 1.52 ] BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, EMPACTA, 2020, REMAP-CAP (tocilizumab), 2021 5 36% 1,500 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
1.19 [0.81 ; 1.75 ] COVACTA (Rosas), 2020 1 0% 438 NA not evaluable clinical improvement (time to event analysis only)detailed results EMPACTA, 2020 1.15 [0.90; 1.47]
1.15 [0.90 ; 1.47 ] EMPACTA, 2020 1 0% NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
EMPACTA, 2020 0.56 [0.32; 0.97]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2021 0.85 [0.78; 0.93]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
Veiga, 2021 1.54 [0.65; 3.63]
0.83 [0.73 ; 0.95 ] BACC Bay Tocilizumab Trial, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, EMPACTA, 2020, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Veiga, 2021 8 12% 5,071 moderate not evaluable hospital dischargedetailed results EMPACTA, 2020 1.16 [0.90; 1.49]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.03 [0.88 ; 1.19 ] EMPACTA, 2020, MARIPOSA, 2021, Rosas (REMDACTA), 2021 3 0% 649 moderate not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
MARIPOSA, 2021 0.88 [0.37; 2.10]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
Rutgers, 2021 0.65 [0.35; 1.24]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
0.78 [0.56 ; 1.08 ] COVACTA (Rosas), 2020, MARIPOSA, 2021, RCT-TCZ-COVID-19, 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021 5 0% 1,029 moderate serious radiologic improvement (14-day)detailed results NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
0.32 [0.06 ; 1.63 ] NCT04310228-FAVI (Zhao), 2020 1 0% NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
0.85 [0.49 ; 1.49 ] COVACTA (Rosas), 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021 3 57% 724 moderate not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
0.91 [0.72 ; 1.15 ] BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 7 0% 1,732 moderate serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
1.51 [0.94 ; 2.42 ] COVACTA (Rosas), 2020, Dongsheng Wang, 2020, NCT04310228-FAVI (Zhao), 2020, Rosas (REMDACTA), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021 6 62% 1,466 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 11:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290